HaiXiang Pharmaceuticals: Wholly-owned subsidiary passes on-site inspection by the US FDA.

Haixiang Pharmaceutical announced that its wholly-owned subsidiary, Zhejiang Haixiang Chuannan Pharmaceutical Co., Ltd., underwent an on-site cGMP inspection by the US Food and Drug Administration from October 27, 2025 to October 31, 2025. Recently, the company received the on-site inspection report issued by the FDA through Chuannan Pharmaceutical, which indicated that Chuannan Pharmaceutical meets the requirements of US drug cGMP and passed the inspection.